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Human norovirus (HuNoV) is the major cause of acute nonbacterial gastroenteritis worldwide but has no clear animal res-
ervoir. HuNoV can persist after the resolution of symptoms, and this persistence may be essential for viral maintenance
within the population. Many strains of the related murine norovirus (MNV) also persist, providing a tractable animal
model for studying norovirus (NoV) persistence. We have used recombinant cDNA clones of representative persistent
(CR6) and nonpersistent (CW3) strains to identify a domain within the nonstructural gene NS1/2 that is necessary and suf-
ficient for persistence. Furthermore, we found that a single change of aspartic acid to glutamic acid in CW3 NS1/2 was suf-
ficient for persistence. This same conservative change also caused increased growth of CW3 in the proximal colon, which
we found to be a major tissue reservoir of MNV persistence, suggesting that NS1/2 determines viral tropism that is neces-
sary for persistence. These findings represent the first identified function for NoV NS1/2 during infection and establish a
novel model system for the study of enteric viral persistence.
Human noroviruses (HuNoVs) are the leading cause of non-bacterial gastroenteritis and are a significant public health
problemworldwide, causing both outbreaks and sporadic cases of
acute gastrointestinal disease (reviewed in references 1, 2, and 3).
There is no evidence for an animal reservoir of HuNoV, suggest-
ing that asymptomatic shedding within the human population
initiates symptomatic infection. Indeed, PCR-based detection has
shown that HuNoVs are present in asymptomatic individuals
within a variety of communities and ranges in prevalence from 3
to 13% (4–7). Furthermore, experimental infection of volunteers
revealed that some individuals continue to shed virus for up to
weeks after the resolution of symptoms (8), and there are exam-
ples where outbreaks likely originated with asymptomatic
HuNoV shedders (9–11). Taken together, these studies demon-
strate that asymptomatic and persistent infections are an impor-
tant aspect of HuNoV biology. However, the molecular mecha-
nisms of NoV persistence remain incompletely understood.
Noroviruses (NoVs) are positive-sense, single-stranded RNA
viruses in the calicivirus family. They are classified into five genetic
groups (genogroups), with HuNoVs in genogroups I, II, and IV
(GI, GII, and GIV, respectively), bovine noroviruses in GIII, and
murine noroviruses (MNV) inGV (12). TheNoV genome is7.5
kb in length and encodes three open reading frames (ORFs) (13),
with an additionalORF4 inMNV(14, 15).ORF1 encodes theNoV
nonstructural polyprotein which is cleaved into six mature pep-
tides (NS1/2 and NS3 through NS7) by the ORF1-encoded viral
protease NS6 (16–18). ORF2 encodes themajor structural protein
(VP1), which self assembles into the icosahedral viral capsid (19),
and ORF3 encodes a minor structural protein (VP2) (20). MNV
ORF4 is an alternate reading frame within ORF2 and encodes
virulence factor 1 (VF1) (14).
NS1/2 is the most N-terminal viral protein encoded by ORF1.
The cleavage site between NS1/2 and NS3 has been confirmed by
mutagenesis studies, and the position of this cleavage is conserved
among all NoVs. All genera of caliciviruses other than NoVs have
an additional viral protease cleavage site within the region homol-
ogous to NS1/2, resulting in two mature viral proteins derived
from this region (21–23). It is possible that some NoVs have lost
this cleavage event, but there is one report of additional cleavage of
the human NS1/2 protein in cells transfected with HuNoV ORF1
(24), and MNV NS1/2 can be cleaved by caspase 3 (18). NS1/2
localizes to organelles in the secretory pathway (25, 26), and
HuNoV NS1/2 disrupts protein secretion in transfected cells (25,
27). However, very little is known about the function of NS1/2 in
NoV replication or pathogenesis.
Similar to HuNoV, MNV establishes persistent asymptomatic
infection (15, 28) and therefore represents an ideal model system
in which to study NoV persistence. While most strains of MNV
persist, the strain MNV1 is cleared. MNV1 was identified as a
cause of lethality in RAG/STAT1 knockout mice (29), and it was
passaged intracranially in these mice until a culture system was
established (30). While MNV1 rapidly kills STAT1 knockout
mice, it persists avirulently in RAG knockout mice and is cleared
from immune-sufficient mice (29, 31). Subsequently, many
closely related strains of MNV isolated from stool samples were
shown to persist in immune-sufficient mice (15, 28). One of these
persistent stool isolates, CR6, has been shown to be avirulent in
STAT1 knockout mice, demonstrating a second phenotypic dis-
tinction from MNV1 (31). A reverse genetics system for MNV
exists (32), making phenotypic analyses of MNV1 and persistent
strains possible (14, 31, 33, 34). The increased virulence of MNV1
has been linked to the protruding domain of the capsid gene (31,
33), but the gene responsible for MNV persistence has not been
identified.
Here, we used recombinant cDNA clones of the nonpersistent
strainMNV1.CW3 (subsequently referred to as CW3) and persis-
tent strain CR6 to identify a genetic determinant of persistence. In
contrast to virulence in STAT1 knockout mice (31), reciprocal
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replacement of the capsid gene did not alter persistence. Instead,
the NS1/2 gene of CR6 enabled persistence of CW3. Within
NS1/2, we further narrowed the determinant of persistence to the
5= domain and to a single amino acidwithin this domain. Further-
more, this same determinant increased growth of CW3 in the
proximal colon, a major reservoir of CR6 persistence. This is the
first demonstrated function for NS1/2 during infection and
the first report of a protein other than the MNV capsid to alter
viral tropism. This is also the first study identifying a genetic de-
terminant for enteric viral persistence.
MATERIALS AND METHODS
Generation of recombinant MNV stocks. Construction of molecular
clones of CW3 (EF014462.1) and CR6 (JQ237823) and the strategy for
cloning of viral gene substitutions have been previously described (31).
Primers used for the substitutions of NS1/2 5= and 3= domains wereNS1/2
forward (5=-GTGAAATGAGGATGGCAACGCCATCTTC-3=), 5= NS1/2
reverse (5=-GCGTCCTCCGCATGGGAGGGCGC-3=), 3= NS1/2 forward
(5=-GCGCCCTCCCATGCGGAGGAC-3=), and CR6 3= NS1/2 reverse
(5=-AGGTCGAAGGGCCCTTCGGCCTGCCA-3=).
Generation of viral stocks from plasmids carrying MNV was per-
formed as described previously (31) with minor modifications. Briefly,
plasmids were transfected into 293T cells with TransIT-LT1 (Mirus Bio,
Madison, WI), and virus was recovered 48 h posttransfection by freezing
and thawing. Clarified 293T supernatants were passaged one to two times
on RAW264.7 cells at a multiplicity of infection (MOI) of 0.05, and
virus was recovered 48 h postinfection. Virus-containing RAW264.7 cell
supernatants were cleared of debris by centrifugation for 2 min at
18,000 g. All viral stocks were derived from cDNA clones rather than
serially passaged MNV isolates.
Mice and infections.C57BL/6mice (stock number 000664) were pur-
chased from Jackson Laboratories (BarHarbor,ME) andhoused atWash-
ington University School of Medicine under specific-pathogen-free con-
ditions (35) according to university guidelines. Cages of male or female
mice were inoculated with virus at 6 to 8 weeks of age by the oral route in
a volume of 25 to 35 l. A dose of 3  104 PFU was used for all experi-
ments, with one exception (1 106 PFU; see Fig. 5E).
Stool and tissues were harvested into 2-ml tubes (Sarstedt, Germany)
with 1-mMdiameter zirconia/silica beads (Biospec, Bartlesville, OK). Tis-
sues were flash frozen in a bath of ethanol and dry ice and either processed
on the same day or stored at80°C.
Plaque assay. Culture of RAW264.7 cells and the plaque assay for
determining the titer of virus stocks was performed as described previ-
ously (31). Growth curve plaque assays utilized suspension-adapted
RAW264.7 cellsmaintained inminimal essentialmedium (MEM) supple-
mented with 10% bovine serum, 1%nonessential amino acids, 100g/ml
penicillin-streptomycin, 2 mM L-glutamine, 10 mMHEPES, and 0.225%
sodium bicarbonate. RAW264.7 cells were plated on 6-well plates at a
density of 2  106 cells per well. Sixteen to 24 h later, medium was re-
moved and 10-fold serial dilutions of virus inoculumwere added at 500l
per well. Plates were incubated for 1 h at room temperature on a rocking
platform before removing the inoculum and overlaying the cells with 2ml
per well of 1%methylcellulose inMEM supplemented with 10% fetal calf
serum, 100 g/ml penicillin-streptomycin, 2 mM L-glutamine, 10 mM
HEPES. Plates were incubated at 37°C for 3 to 4 days, and plaques were
visualized by staining with 0.2% crystal violet and 20% ethanol.
Quantitative reverse transcription-PCR. RNA from stool was iso-
lated using either an RNeasy Miniprep (Qiagen, Valencia, CA) or Quick-
RNA Miniprep (Zymoresearch, Irvine, CA) kit. RNA from tissues was
isolated using TRIzol (Life Technologies, Carlsbad, CA) according to the
manufacturer’s protocol. Fivel of RNA from stool or 1g of RNA from
tissue was used as a template for cDNA synthesis with the ImPromII
reverse transcriptase system (Promega, Madison, WI). When evident in
the melting curve analysis, DNA contamination was removed using the
DNAfree kit (Life Technologies).
MNV TaqMan was performed as described previously (36). MNV
genome quantities from tissue samples were normalized to the house-
keeping gene of ribosomal protein S29 (RPS29). SYBR green quantitative
PCR for RPS29 was performed with the forward primer 5=-AGCAGCTC
TACTGGAGTCACC-3= and reverse primer 5=-AGGTCGCTTAGTCCA
ACTTAATG-3= at a concentration of 0.2 M in 1 Power SYBR green
master mix (Life Technologies). Cycling parameters were identical to
those forMNVTaqManwith the exception of an additionalmelting curve
analysis.
Statistical analysis. Data were analyzed with Prism 5 software
(GraphPad Software, San Diego, CA). In all graphs, three asterisks indi-
cate P 0.001, two asterisks indicate P 0.01, one asterisk indicates P
0.05, and n.s. indicates not significant (P  0.05) as determined by one-
way analysis of variance (ANOVA) with Tukey’s posttest (single-time-
point experiments) or two-way ANOVA with Bonferroni’s posttest
(kinetic experiments). All error bars depict standard errors of the means.
RESULTS
CW3 and CR6 differ in quantity and persistence of shedding in
stool. Molecular clones of the representative nonpersistent and
persistent strains CW3 and CR6 were used for a kinetic compari-
son of fecal shedding. CR6was shed by six out of eightmice on day
three and reached a peak level of shedding by day seven postinfec-
tion. The day seven shedding of CW3 was significantly lower than
that of CR6, and CW3was not detected inmore than 50% ofmice
at any time point. Average CW3 shedding decreased below the
limit of detection at day 14 and remained undetectable at days 21
and 35 (Fig. 1). In contrast, CR6 was consistently shed between
days 21 and 70 with no observed clearance in any animals (Fig. 1).
Therefore, CR6 infection leads to long-lived persistent shedding
as well as significantly greater shedding than CW3 during acute
infection.
MNVcapsid does not determine persistence.VP1was a likely
candidate for determining MNV persistence due to its role in im-
munity, lethality, and tropism (31, 33, 34, 37, 38). Therefore, we
assessed the shedding of viruses with reciprocal substitutions in
the VP1 gene (including the overlapping VF1 gene, as depicted in
Fig. 2A). The number of genome copies in the stool at 35 days
postinfection was not significantly different between CW3 and
CW3 carrying the VP1 gene from CR6 (CW3-VP1) or between
CR6 and CR6 carrying the VP1 gene from CW3 (CR6-VP1) (Fig.
2B). These data indicate that a gene or genes other than VP1 are
required for persistent infection by MNV.
5= Region of the NS1/2 gene is necessary and sufficient for
persistence. To determine whether a CR6 gene other than VP1
was sufficient to enable CW3 persistence, we tested additional
CW3 viruses with single CR6-derived gene replacements (Fig.
2A) (31). A comparison of threshold cycle (CT) values revealed



















FIG 1 CW3 and CR6 differ in quantity and persistence of viral shedding in
stool. Stool was collected at the indicated days postinfection, and the genome
copy number was determined by quantitative PCR. Data show themean shed-
ding of at least four mice per time point.
Nice et al.
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that shedding of CW3-NS1/2 was significantly greater than that
of all other single-gene substitutions (Fig. 2C). To confirm and
quantify the result of this screen, we generated two additional
viral stocks of CW3-NS1/2 and tested all three stocks for per-
sistent shedding. All three biological replicates of CW3-NS1/2
were detected in stool at 35 days postinfection, and the quantity
of MNV genomes was not significantly different from that of
CR6 (Fig. 2D). The reciprocal insertion of NS1/2 from CW3
into CR6 did not generate virus and could not be tested for
persistence. These findings indicate that the NS1/2 gene of CR6
is sufficient to enable CW3 persistence.
The NS1/2 gene encodes a 3= domain conserved among NoVs
(39) and a 5= domain that is more divergent. To narrow the per-
sistence determinant to a single domain, we generated CW3 with
the 5= domain of CR6 NS1/2 (CW3-5= NS1/2) and CW3 with the
3= domain of CR6 NS1/2 (CW3-3= NS1/2) as depicted in Fig. 2A.
While persistent CW3-3= NS1/2 shedding was not detected,
CW3-5= NS1/2 shedding was indistinguishable from that of CR6
(Fig. 2E) To test whether the 5= NS1/2 domain was also necessary
for persistence, we generated CR6 with a CW3 substitution in the
5= domain of the NS1/2 gene (CR6-5=NS1/2). Persistent shedding
of CR6-5= NS1/2 was significantly lower than that of CR6 and not
significantly different from that of CW3 (Fig. 2E). Taken together,
these data demonstrate that the 5= domain of the NS1/2 gene is
necessary and sufficient for MNV persistence.
A change of aspartic acid to glutamic acid at amino acid 94 of
NS1/2 is sufficient for persistence.CR6 is one of seven persistent
strains identified to date (15, 28). To test whether CW3has unique
polymorphisms that correlate with its inability to persist, we ana-
lyzed the 5= domain of NS1/2 from CW3 and the seven persistent
MNV strains (Fig. 3A). Amino acid alignment showed that only a
single residue was both unique to CW3 and conserved among the
persistent strains of MNV. This difference was a conservative
change at amino acid 94, with glutamic acid present in persistent
strains and aspartic acid present in CW3 (Fig. 3A). To assess
whether this difference was involved in determining persistence,
we generated a mutant of CW3 that encoded the conserved glu-
tamic acid present in CR6 (CW3D94E). Additionally, we made the
reciprocalmutation inCR6, changing the conserved glutamic acid
to an aspartic acid (CR6E94D). CR6 persistent shedding was not
significantly changed by the E94D mutation (Fig. 3B), and se-
quencing demonstrated no reversion to E94 in vivo (data not
shown). In contrast, CW3 shedding was significantly increased by
the D94E mutation to levels that were not significantly different
from those of CR6 (Fig. 3B). Furthermore, aD94Emutation in the
nonpersistent CR6-5=NS1/2 chimera rescued its ability to persist.
This striking result demonstrates that glutamic acid at amino acid
94 of NS1/2 is sufficient, though not necessary, for persistence.
Persistent and nonpersistent viruses have similar in vitro
growth. The association of NS1/2 with cellular membranes and
D
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FIG 2 5= Domain of NS1/2 is necessary and sufficient for persistence. (A) Diagram of the MNV genome and the genomes of MNV chimeras used in panels B to
E tomap the persistence trait. (B to E)Mice were inoculated with the indicatedMNV strains. Stool was collected 35 days postinfection, andMNV genomes were
detected by quantitative PCR. (B) Comparison of VP1-substituted strains. (C) A screen of additional single-gene substitutions. (D)Confirmation of CW3-NS1/2
persistence with three independent viral stocks. (E) Comparison ofNS1/2 domain-substituted viruses. Data in panels C andD are from single experiments; those
in panels B and E are combined from at least two experiments for each virus. 1/Ct indicates the inverse of the threshold cycle.
NS1/2 Determines MNV Tropism and Persistence
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the viral replication complex (40) suggested that it has a role in
viral replication that is altered by the persistence determinant. To
test this hypothesis, we compared in vitro growth of the persistent
viruses CW3D94E and CR6 to that of the nonpersistent viruses
CW3 and CR6-5= NS1/2. Infection of RAW264.7 cells at an MOI
of 5 revealed no significant overall difference in growth at any time
postinfection between any pair of persistent and nonpersistent
viruses (Fig. 4). At an MOI of 0.05 there were also no significant
differences other than at 4 h postinfection between CR6 and
CR6-5= NS1/2 (P 0.05) (Fig. 4). However, there were no differ-
ences between CW3 and CW3D94E at any time that would indicate
a role for this early growth difference in determining the persis-
tence phenotype. Together, these data show that the persistence
determinant has little to no effect on in vitro growth in RAW264.7
cells.
CR6 grows better than CW3 in the proximal colon.While no
growth difference was seen in RAW264.7 cells, the significant dif-
ference in fecal shedding between CW3 and CR6 on day seven
(Fig. 1) suggested that there was a difference in enteric growth
during the early stages of infection in vivo. To identify the prefer-
ential enteric site(s) of CR6 replication, relative levels of persistent
CR6 were measured in anatomically distinct regions along the
gastrointestinal (GI) tract. CR6 was detected in the proximal co-
lon at levels significantly greater than those of all other GI regions
with the exception of the cecum (Fig. 5A). This observation was
supported by recent publications which also predominantly de-
tected persistentMNVstrains in the cecumand/or proximal colon
(34, 41).
Therefore, the proximal colon was included as the representa-
tive enteric tissue in a comparison between CR6 and CW3 growth
during acute infection. Spleen andmesenteric lymphnode (MLN)
were also included in the comparison because MNV grows in
macrophages and dendritic cells (DCs) and can spread to these
tissues. The peak titer of both strains in all tissues was reached by
day seven (Fig. 5B). In the proximal colon, CR6 grew significantly
better than CW3 from day 3 through 14, and CW3 was only min-
imally detected at any time point (Fig. 5B, left). In the spleen, CW3
grew significantly better than CR6 between days 3 and 7 but was
cleared by day 14 (Fig. 5B, middle). This difference in the spleen
was in accordance with recent publications demonstrating the
FIG 3 Change of aspartic acid to glutamic acid at position 94 of NS1/2 is
sufficient for persistence. (A) Alignment of the first 117 amino acids of CW3
with CR6 and six additional persistent strains of MNV (accession numbers
DQ223041, DQ223042, DQ223043, EU004672, EU004673, and EU004677
[15, 28]). Conserved amino acid residues are gray, and nonconserved residues
are black. The arrow indicates a unique aspartic acid residue at position 94 of
CW3. (B) Mice were inoculated with the indicated MNV strains. Stool was
collected between 28 and 36 days postinfection, and MNV genomes were de-
tected by quantitative PCR. Data are combined from at least two experiments
for each virus.
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FIG 4 Viral mutants with altered persistence phenotype have similar in vitro
growth. RAW264.7 cells were infected at an MOI of either 0.05 or 5, and viral
growth was measured by plaque assay at the indicated times postinfection.
Data are combined from three experiments.
Nice et al.
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ability of CW3 and MNV1 to spread systemically (31, 42) and
indicates that the failure of CW3 to persist in the intestine is not
due to a failure to establish infection. Both strains were detected in
the MLN with no significant difference before day 14 when CW3
was cleared (Fig. 5B, right). Taken together, these data demon-
strate significant differences in tissue tropism between CW3 and
CR6 in the spleen and proximal colon, the latter being amajor site
of persistence.
NS1/2 amino acid 94, rather than capsid, determines growth
in the proximal colon. Other studies have mapped MNV1 tro-
pism changes toVP1 (31, 34), sowe usedCW3-VP1 andCR6-VP1
to test the role of VP1 in determining the tropism differences
revealed in Fig. 5B. Growth of CW3-VP1 in the proximal colon 7
days after infection was not significantly higher than that of CW3,
and growth of CR6-VP1 was not significantly lower than that of
CR6 (Fig. 5C, left). In the spleen, growth of CW3-VP1 was signif-
icantly lower than that of CW3 and not significantly different
from that of CR6; CR6-VP1 growth was significantly higher than
that of CR6 and not significantly different from that of CW3 (Fig.
5C, middle). Therefore, VP1 determines CW3 tropism for the
spleen but not CR6 tropism for the proximal colon.
In parallel, we tested day seven growth of NS1/2 mutants to
address the effect of the persistence determinant on tropism dur-
ing acute infection. The persistent viruses CW3-NS1/2 and
CW3D94E grew in both the spleen and proximal colon at levels
significantly higher than the nonpersistent CR6-5= NS1/2, which
was not detected in any tissue (Fig. 5D). Strikingly, introduction

















































































































































































































































































































































FIG 5 NS1/2 and amino acid 94 determine growth in the proximal colon, a major reservoir of persistent MNV. (A to E) Tissues were harvested from
MNV-infected mice, and the genome copy number was measured by quantitative PCR. (A) Detection of CR6 in regions of the gastrointestinal tract 35 days
postinfection. Data are combined from two experiments for a total of fivemice. (B) A kinetic comparison of titers in spleen, proximal colon, andMLN following
infectionwith either CW3orCR6. Data are combined from three experiments for a total of ninemice per data point. (C andD)Detection of the indicated viruses
in tissues at day seven postinfection.Data are combined fromat least two experiments for a total of at least eightmice for each data point. CW3 andCR6data from
day seven in panel B are shown in panel C for reference. (E) Detection of CR6-VP1 in the indicated tissues at 3 or 35 days postinfection with 1 106 PFU. Data
are combined from two experiments for a total of six mice per data point.
NS1/2 Determines MNV Tropism and Persistence
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increased growth in the colon without a significant change in the
spleen (Fig. 5D, CR6-5= NS1/2D94E). Therefore, D94E is sufficient
for growth in the proximal colon, but not in the spleen, during
acute infection.
MNV persistence is restricted to the intestine. The correla-
tion between persistent fecal shedding and growth in the proximal
colon during acute infection (Fig. 2E, 3B, and 5D) raised the pos-
sibility that MNV persistence is an intestine-specific phenotype.
CR6 did not persist outside the intestine and associated lymphoid
tissue, but its replication during acute infection was also restricted
to these same sites (Fig. 5B and data not shown). Therefore, we
took advantage of the expanded tropismofCR6-VP1 during acute
infection to test this hypothesis. On day three postinfection with
1 106 PFU, CR6-VP1 had grown in both enteric tissues (Fig. 5E,
proximal colon and MLN) as well as systemic tissues (Fig. 5E,
spleen and liver). However, while CR6-VP1was still present in the
intestine on day 35, it was reduced to the limit of detection in the
spleen and liver (Fig. 5E). This result shows thatMNV persistence
is specific to the intestine and provides a possible explanation for
the correlation between enteric growth during acute infection and
persistence.
DISCUSSION
The findings presented here demonstrate that the 5= domain of
NS1/2 is necessary and sufficient for MNV persistence. Further-
more, a single conservative change from aspartic acid to glutamic
acid at amino acid 94 within this domain is sufficient for CW3 to
persist. This D94E change also determines tropism for the proxi-
mal colon but not the spleen during acute infection. Notably, the
proximal colon is a major site of MNV persistence, while the
spleen does not support persistent replication.
MNVas amodel of persistent enteric viral infection.There is
no clear animal reservoir for HuNoV, suggesting that it has other
adaptations for viral maintenance between outbreaks. Asymp-
tomatic and persistent shedding is likely to be one way that
HuNoVs are maintained (4–7, 11), yet many questions remain
about the mechanism of NoV persistence. Furthermore, while
asymptomatic shedding has been demonstrated for many enteric
viruses (43–45), a tractable model has not been established in
which to study enteric persistence. We have characterized a novel
model of persistence and identified the first genetic determinant
of enteric persistence. Future study using the MNVmodel system
has the exciting potential to reveal general principles of enteric
persistence and host-pathogen interactions in the intestine.
Relationship between enteric growth and persistence. We
have shown a correlation of persistent sheddingwith growth in the
colon, but not the spleen, during acute infection (Fig. 2E, 3B, and
5D). This correlation suggests that efficient colonic replication is
required for persistence. Support for this idea comes from the fact
thatCR6-VP1,which has broad early tissue tropism, persists in the
colon and MLN but not systemic sites (Fig. 5E). Therefore, effi-
cient early replication in colon may correlate with persistence,
because MNV persistence is restricted to enteric tissues. The im-
portance of enteric growth may reflect a requirement for fecal
shedding and reexposure, replication in enteric cell types, or in-
duction of enteric immune responses.
CR6 infection results in increased fecal shedding compared to
CW3 (Fig. 1). Consequently, there are likely an increased number
of virions in the environment and more frequent reexposure of
the intestinal epithelium. Antigenic drift within a cage may in-
crease exposure to viral mutations that outpace immune elimina-
tion and result in persistence. Sequencing of CW3D94E from per-
sistently infected mice reveals that mutations in the protruding
domain of the capsid are in fact present (T. J. Nice, data not
shown). Furthermore, there is evidence that this type of selection
takes place in human populations and is important for persistence
of HuNoV (46). It is notable that infection with 3  107 PFU of
CW3, rather than the 3 104 PFU used here, results in apprecia-
ble shedding in the stool during acute infection and yet is ulti-
mately cleared (35). Therefore, while it is still possible that CR6
and other persistent strains have a unique ability to promote an-
tigenic drift, reexposure to shed MNV per se is not likely to be
sufficient to explain the capacity to persist.
A separate, but not mutually exclusive, hypothesis to explain
the importance of enteric growth is that characteristics of the im-
mune system unique to this anatomical location are critical for
persistence. The mammalian mucosal immune system has
evolved in proximity to abundant commensal microbes and has a
unique requirement for regulatory mechanisms that prevent ex-
cessive inflammatory responses to these microbes (47–51). These
mechanisms include both intestine-specific differentiation pro-
grams for innate leukocytes (52, 53) and the related ability to
generate regulatory T cell responses (54). An analogous regulatory
immune response may be required for tolerance of persistent
MNV in the intestine. Alternatively, because MNV is known to
replicate in macrophages and dendritic cells (30), the unique dif-
ferentiation states of these cell types in the intestine may provide
cell-intrinsic growth requirements for persistent replication. Clar-
ification of the anatomical requirements forMNVpersistence will
provide complementary insights into molecular studies of NS1/2
in establishing the mechanism of persistence in this novel model
system.
Potentialmechanisms ofNS1/2 in persistence. Studies impli-
cating NS1/2 in membrane reorganization and formation of the
replication complex (27, 40) raise the possibility that NS1/2 deter-
mines persistence through changes in MNV replication. We
found no evidence for an in vitro replication function of theNS1/2
persistence determinant in RAW264.7 cells (Fig. 4). However, its
role in determining growth in the proximal colon during acute
infection (Fig. 5D) means that NS1/2 may have functions specific
to a colonic cell type. Therefore, a role for NS1/2 in cell type-
specific viral replication remains a possibility, and identification
of the colonic cell types in whichMNVpersists will be necessary to
address this possibility experimentally.
While there aremultiple potentialmechanisms for persistence,
all persistent viruses share the capacity to prevent clearance by the
immune system. Strategies for preventing immune elimination
include inhibition of antigen presentation or innate immune sig-
naling, evasion of adaptive immunity through mutation of im-
mune-dominant epitopes, and infection of an immune-privileged
site (55–57). Therefore, potential immune-modulatory functions
of NS1/2 must also be considered in addition to basic replicative
functions. Humoral immunity, cellular immunity, and innate im-
munity cooperate to clear infection with MNV1 (29, 37, 38), so
NS1/2-mediated evasion of any of these immune components
could account for its role in persistence. Identification of NS1/2
structures and interacting partners will be required to generate
more detailed hypotheses about a role for NS1/2 in immunemod-
ulation.
Domains of NS1/2. TheNS1/2 caspase cleavage sites (18) have
Nice et al.
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been used by us and others (58) to define NS1/2 domains. The
region 5= of the caspase cleavage site, which contains the amino
acid 94 persistence determinant, is poorly conserved amongNoVs
and is also poorly conserved within genogroups. The region 3= of
the caspase cleavage site, however, is conserved among NoVs and
is bioinformatically predicted to fold into a permutated papain-
like fold (39). Characteristic of this fold, there are conserved cys-
teine, histidine, and histidine/asparagine residues predicted to
form a catalytic triad. Supportive evidence for a catalytic function
comes from a study of a picornaviral orthologue, where mutation
of the conserved cysteine was found to block positive-strand RNA
synthesis in an in vitro replication system (59). Similarly,mutation
of the conserved cysteine or histidine in MNV prevents recovery
of plaquable virus from the reverse genetics system (Nice, unpub-
lished). Whether the persistence determinant in the 5= domain is
related to a hypothetical catalytic function of the 3= domain re-
quires further biochemical and functional studies.
We find that the 5= NS1/2 domain determines persistence and
colonic growth of bothCW3 andCR6 (Fig. 2E and 5D), but amino
acid 94 determines persistence of CW3 only (Fig. 3B). This sug-
gests that amino acid 94 interacts with CW3-specific sequences.
The fact that the D94E mutation can increase colonic growth of
bothCW3 andCR6-5=NS1/2 (CW3D94E andCR6-5=NS1/2D94E in
Fig. 5D) suggests that the CW3-specific interaction of amino acid
94 is within the 5= domain. While these data do not preclude an
additional role for strain-independent intergenic interactions of
the entire 5= NS1/2 domain, they support the hypothesis that dis-
crete domains exist within NS1/2. The separation of these do-
mains by caspase 3 cleavage and the demonstrated induction of
apoptosis during MNV infection (18, 60) raises the intriguing
possibility that the MNV NS1/2 5= domain acts independently of
the 3= domain to determine persistence and colonic tropism.
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